New developments in self-injection therapy for erectile dysfunction

British Journal of Urology

Volumn 81, Issue 4, 1998, Pages 599-603

  Gingell, J C ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CHLORPROMAZINE; MOXISYLYTE; PAPAVERINE; PERIPHERAL VASODILATING AGENT; PROSTAGLANDIN E1; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

HEMATOMA; HUMAN; HYPOTENSION; IMPOTENCE; INJECTION PAIN; MALE; PRIAPISM; PRIORITY JOURNAL; SELF INJECTION; SHORT SURVEY; SYNCOPE; VERTIGO;

ALPROSTADIL; CALCITONIN GENE-RELATED PEPTIDE; CHLORPROMAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMPOTENCE; INJECTIONS; MALE; MOXISYLYTE; PAPAVERINE; PATIENT SATISFACTION; PHENTOLAMINE; SELF ADMINISTRATION; SYMPATHOLYTICS; TREATMENT OUTCOME; VASOACTIVE INTESTINAL PEPTIDE; VASODILATOR AGENTS;

EID: 0031845244     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00600.x     Document Type: Short Survey

References (34)

1. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982; 11: 938
2. Brindley GS. Cavernosal alpha blockage: a new technique for investigating and treating erectile impotence. Br J Psych 1983; 143: 332-7
3. Zorgniotti AW, Lefleur RS. Autoinjection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985; 133: 39-41
4. Levine SB, Althol SE. Turner LA et al. Side effects of selfadministration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 54
5. Hu KN, Burks C, Christy WC. Fibrosis of tunica albuginea: complication of long-term intracavernous pharmalogical self-injection. J Urol 1987: 138: 404
6. Abozeid M, Junemann KP, Luo JA, Lue TF, Yen TSB, Tanagho EA. Chronic papaverine treatment: the effect of repeated injections on the simian erectile response and penile tissue. J Urol 1987; 138: 1263
7. Lakin MM, Montague DK, Mendendorp SV, Tesar L, Schover LR. Intracavernous injection therapy: analysis of results and complications. J Urol 1990; 143: 1138
8. Junemann KP, Alken P. Pharmacotherapy of erectile dysfunction: a review. Int J Impôt Res 1989; 1: 71
9. ABPI. Compendium of data sheets and summaries of product characteristics 1996-97. London: Datapharm Publications Ltd, 1996
10. Stackl W. Hanson R, Marberger M. The use of prostaglandin El for the diagnosis and treatment of erectile dysfunction. World] Urol 1990: 8: 84-6
11. Linet 01. Ogrine FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New Eng ]M ed 1996: 334: 873-7
12. Porst H, van Ahlen H, Block T et al. Intracavernous selfinjection of prostaglandin El in the therapy of erectile dysfunction. VAS A 1989 (Suppl): 28: 50-6
13. Porst H. The rationale for prostaglandin El in erectile failure: a survey of worldwide experience. J Urol 1996: 155: 802-15
14. Gay S, Hogg D. Gingell JC. An autoinjector for Caverject. lut I Imp Res 1996; 8: 3144. D88
15. 5 Anderson KE. Holmquist F, Wagner G. Pharmacology of drugs used for treatment of erectile dysfunction and priapism. Int ] Imp Res 1991: 6: 155-72
16. Templeton AA. Cooper T. Kelly RW. Prostaglandin concentrations in the semen of fertile men. J Reprod Pert 1978; 58: 147-50
17. 7 Pryor JP. Caverject and erectile dysfunction. J Sexual Health 1994: S4-S5
18. Krane RJ. Goldestein I, Saenz de Tejada I. Impotence. New l-iifi] Med 1989: 321: 1648-59
19. Chew KK. Earle CM. Stuckley BGA. Keogh EJ. Penile fibrosis in intracavernosal PGE1 injection therapy for erectile dysfunction. Int J Imp Res 1996; 8: 143
20. Jeunemann K-P. Manning M. Krautschick A. Alken P. 1 5 years of injection therapy in erectile dysfunction -a review. Int }Imp Res 1996: 8: 14
21. Buvat ]. Costa P. Morlier D et al. Erectile response to intracavernosal injection of alprostadil compared with moxisylyte chlorhydrate in chronic erectile dysfunction: a double-blind, multi-centre stud in 156 patients. Int J Imp Res 1996; 8: 114
22. Braga RS. Braga LTCM. Chlorpromazine: a good substitute drug for phentolamine -a follow up study of 174 patients. Int }Imp Res 1996; 8: 113
23. Kulkarni VR, Shah RS, Gupte DM. Mehte MK. A clinical study of the erection- inducing effects of intra cavernosal chlorpromazine. Int J Imp Res 1996: 8: 143
24. Ottesen B. Wagner G. Virag R, Fahrenkrug J. Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br Med J 1984: 288: 9
25. Polak JM, Gu J. Mina S. Bloom SR. VIPergic nerves in the penis. Lancet 1981: 2: 217
26. Wagner G. Gerstenberg 1C. Intracavernosal injection of vasoactive intestinal polypeptide (VIP) does not induce erection in man per se. World }Urol 1987: 5: 171
27. Kiely EA. Bloom SR, Williams G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br }Urol 1989: 64: 191
28. Roy JB, Pétrone RL. Said SI. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol 1990: 14I: 302
29. Gerstenberg TC. Metz P. Ottesen B. Fahrenkrug J. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992: 147: 1277-9
30. McMahon CG. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction, hit ] Imp Res 1996: 8: 233-6
31. Gerstenberg TC. Long term use of vasopotin in the treatment of erectile dysfunction. Int j Imp Res 1995: 7: 5
32. Djamilian M. Stief CG. Kuczyk M, Jonas I". Follow up results of a combination of calcitonin gene-related peptide and prostaglandin El in the treatment of erectile dysfunction. J Urol 1993: 149: 1296-8
33. Truss MC. Becker AJ, Thon WF et al. Intracavernous calcitonin gene-related pt-plide plus prostaglandin El: possible alternative to penile implants in selected patients. Eur J Urol 1994: 26: 1-108
34. J.C. Gingell. MB, FRCS. Consultant Urologist, Bristol Urological Institute, Southmead Hospital. Bristol BSU) 5XB. UK.